Adamis Pharmaceuticals Statistics
Share Statistics
Adamis Pharmaceuticals has 9.36M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 9.36M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,802 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.97 and the forward
PE ratio is null.
Adamis Pharmaceuticals's PEG ratio is
0.04.
| PE Ratio | -0.97 |
| Forward PE | n/a |
| PS Ratio | 5.33 |
| Forward PS | n/a |
| PB Ratio | -31.39 |
| P/FCF Ratio | -0.95 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Adamis Pharmaceuticals has an Enterprise Value (EV) of 24.63M.
| EV / Sales | 5.18 |
| EV / EBITDA | -1.01 |
| EV / EBIT | -0.95 |
| EV / FCF | -0.93 |
Financial Position
The company has a current ratio of 0.81,
with a Debt / Equity ratio of -0.42.
| Current Ratio | 0.81 |
| Quick Ratio | 0.7 |
| Debt / Equity | -0.42 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -567.9 |
Financial Efficiency
Return on Equity is 3242.23% and Return on Invested Capital is 5383.58%.
| Return on Equity | 3242.23% |
| Return on Assets | -239.68% |
| Return on Invested Capital | 5383.58% |
| Revenue Per Employee | $432,370.73 |
| Profits Per Employee | $-2,381,764.18 |
| Employee Count | 11 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 4.99 |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by 24.98% in the
last 52 weeks. The beta is 1.28, so Adamis Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | 24.98% |
| 50-Day Moving Average | 1 |
| 200-Day Moving Average | 6.45 |
| Relative Strength Index (RSI) | 43.5 |
| Average Volume (20 Days) | 3,113,594 |
Income Statement
In the last 12 months, Adamis Pharmaceuticals had revenue of 4.76M
and earned -26.2M
in profits. Earnings per share was -12.24.
| Revenue | 4.76M |
| Gross Profit | -1.43M |
| Operating Income | -25.06M |
| Net Income | -26.2M |
| EBITDA | -24.27M |
| EBIT | -1.16B |
| Earnings Per Share (EPS) | -12.24 |
Full Income StatementBalance Sheet
The company has 1.08M in cash and 342.56K in
debt, giving a net cash position of 738.8K.
| Cash & Cash Equivalents | 1.08M |
| Total Debt | 342.56K |
| Net Cash | 738.8K |
| Retained Earnings | -304.56M |
| Total Assets | 8.96B |
| Working Capital | -5.59B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -25.9M
and capital expenditures -680.42K, giving a free cash flow of -26.58M.
| Operating Cash Flow | -25.9M |
| Capital Expenditures | -680.42K |
| Free Cash Flow | -26.58M |
| FCF Per Share | -12.42 |
Full Cash Flow StatementMargins
Gross margin is -30.1%, with operating and profit margins of -526.88% and -550.86%.
| Gross Margin | -30.1% |
| Operating Margin | -526.88% |
| Pretax Margin | -550.82% |
| Profit Margin | -550.86% |
| EBITDA Margin | -510.24% |
| EBIT Margin | -526.88% |
| FCF Margin | -558.88% |
